Dimerix Ltd
ASX:DXB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Dimerix Ltd
Common Shares Outstanding
Dimerix Ltd
Common Shares Outstanding Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Shares Outstanding | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Dimerix Ltd
ASX:DXB
|
Common Shares Outstanding
AU$600.4m
|
CAGR 3-Years
23%
|
CAGR 5-Years
24%
|
CAGR 10-Years
24%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Common Shares Outstanding
$1.3B
|
CAGR 3-Years
18%
|
CAGR 5-Years
17%
|
CAGR 10-Years
13%
|
|
|
CSL Ltd
ASX:CSL
|
Common Shares Outstanding
$482.1m
|
CAGR 3-Years
0%
|
CAGR 5-Years
1%
|
CAGR 10-Years
0%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Common Shares Outstanding
AU$180.8m
|
CAGR 3-Years
4%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Common Shares Outstanding
AU$338.8m
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Common Shares Outstanding
AU$597.2m
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
-12%
|
|
Dimerix Ltd
Glance View
Dimerix Ltd. engages in the investment in research and development of biopharmaceutical drugs. The company is headquartered in Melbourne, Victoria. The firm is engaged in the development of new therapies in areas with unmet medical need. The firm is developing four product indications: Focal Segmental Glomerulosclerosis (FSGS), respiratory complications associated with COVID-19, diabetic kidney disease, and DMX-700 for Chronic Obstructive Pulmonary Disease (COPD), as well as the its Receptor-HIT assay technology. The Company’s pipeline products include DMX-200, DMX-700 and DMX-XXX. DMX-200, which is developed for FSGS, COVID-19 pneumonia patient in ICU and respiratory complications in COVID-19 patients is under Phase III clinical trial. DMX-200, which is developed for diabetic kidney disease is under Phase II clinical trial. DMX-700, which is developed for COPD is under Phase I clinical trial. DMX-XXX is under Phase I clinical trial.
See Also
What is Dimerix Ltd's Common Shares Outstanding?
Common Shares Outstanding
600.4m
AUD
Based on the financial report for Dec 31, 2025, Dimerix Ltd's Common Shares Outstanding amounts to 600.4m AUD.
What is Dimerix Ltd's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 10Y
24%
Over the last year, the Common Shares Outstanding growth was 8%. The average annual Common Shares Outstanding growth rates for Dimerix Ltd have been 23% over the past three years , 24% over the past five years , and 24% over the past ten years .
